DaVita Past Earnings Performance
Past criteria checks 3/6
DaVita's earnings have been declining at an average annual rate of -2.4%, while the Healthcare industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 1.7% per year. DaVita's return on equity is 51%, and it has net margins of 6.5%.
Key information
-2.4%
Earnings growth rate
8.3%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 1.7% |
| Return on equity | 51.0% |
| Net Margin | 6.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How DaVita makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 12,667 | 828 | 1,497 | 0 |
| 30 Jun 24 | 12,524 | 860 | 1,493 | 0 |
| 31 Mar 24 | 12,338 | 816 | 1,505 | 0 |
| 31 Dec 23 | 12,140 | 692 | 1,474 | 0 |
| 30 Sep 23 | 11,911 | 596 | 1,452 | 0 |
| 30 Jun 23 | 11,739 | 454 | 1,441 | 0 |
| 31 Mar 23 | 11,665 | 500 | 1,392 | 0 |
| 31 Dec 22 | 11,610 | 547 | 1,355 | 0 |
| 30 Sep 22 | 11,637 | 680 | 1,298 | 0 |
| 30 Jun 22 | 11,627 | 834 | 1,226 | 0 |
| 31 Mar 22 | 11,616 | 903 | 1,209 | 0 |
| 31 Dec 21 | 11,619 | 978 | 1,195 | 0 |
| 30 Sep 21 | 11,580 | 984 | 1,177 | 0 |
| 30 Jun 21 | 11,566 | 883 | 1,247 | 0 |
| 31 Mar 21 | 11,529 | 791 | 1,230 | 0 |
| 31 Dec 20 | 11,551 | 783 | 1,248 | 0 |
| 30 Sep 20 | 11,544 | 832 | 1,186 | 0 |
| 30 Jun 20 | 11,524 | 824 | 1,122 | 0 |
| 31 Mar 20 | 11,487 | 816 | 1,116 | 0 |
| 31 Dec 19 | 11,388 | 705 | 1,103 | 0 |
| 30 Sep 19 | 11,311 | 623 | 1,093 | 0 |
| 30 Jun 19 | 11,253 | 548 | 1,131 | 0 |
| 31 Mar 19 | 11,300 | 551 | 1,120 | 0 |
| 31 Dec 18 | 11,412 | 616 | 1,135 | 0 |
| 30 Sep 18 | 11,378 | 617 | 1,120 | 0 |
| 30 Jun 18 | 11,299 | 698 | 1,057 | 0 |
| 31 Mar 18 | 11,110 | 652 | 1,056 | 0 |
| 31 Dec 17 | 10,884 | 909 | 1,052 | 0 |
| 30 Sep 17 | 7,773 | 1,065 | 707 | 0 |
| 30 Jun 17 | 8,732 | 1,480 | 825 | 0 |
| 31 Mar 17 | 9,747 | 1,382 | 949 | 0 |
| 31 Dec 16 | 10,696 | 1,038 | 1,057 | 0 |
| 30 Sep 16 | 14,550 | 716 | 1,573 | 0 |
| 30 Jun 16 | 14,347 | 361 | 1,536 | 0 |
| 31 Mar 16 | 14,065 | 478 | 1,497 | 0 |
| 31 Dec 15 | 9,973 | 323 | 1,031 | 0 |
| 30 Sep 15 | 13,565 | 484 | 1,399 | 0 |
| 30 Jun 15 | 13,290 | 452 | 1,369 | 0 |
| 31 Mar 15 | 13,027 | 429 | 1,319 | 0 |
| 31 Dec 14 | 12,781 | 723 | 1,262 | 0 |
| 30 Sep 14 | 12,519 | 727 | 1,224 | 0 |
| 30 Jun 14 | 12,270 | 680 | 1,207 | 0 |
| 31 Mar 14 | 11,971 | 787 | 1,176 | 0 |
| 31 Dec 13 | 11,759 | 620 | 1,176 | 0 |
Quality Earnings: TRL has high quality earnings.
Growing Profit Margin: TRL's current net profit margins (6.5%) are higher than last year (5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRL's earnings have declined by 2.4% per year over the past 5 years.
Accelerating Growth: TRL's earnings growth over the past year (39%) exceeds its 5-year average (-2.4% per year).
Earnings vs Industry: TRL earnings growth over the past year (39%) did not outperform the Healthcare industry 40.5%.
Return on Equity
High ROE: Whilst TRL's Return on Equity (51%) is outstanding, this metric is skewed due to their high level of debt.